Medscape Education is a proud sponsor of the inaugural 2025 Cholestatic Liver Disease Summit, taking place June 26–28 in ...

Up to 59.1% patients enrolled in the study achieved metabolic dysfunction-associated steatohepatitis resolution without ...

Altimmune stock took a huge hit after its liver disease drug, pemvidutide, failed to show strong results in reducing fibrosis ...

Personalised medicine and fibrosis-targeting treatments are key growth areas. The global liver disease treatment market is ...

Lea first spotted a small lump on her right breast but was reassured her 'lumpy boobs' were just due to hormones ...

A woman was diagnosed with incurable stage 4 breast cancer after her tumour was dismissed as 'lumpy boobs' for two years. Lea ...

Fatty liver disease, increasingly prevalent among young individuals, stems from unhealthy diets, sedentary lifestyles, and ...

In May 2025, researchers announced that K.J. Muldoon, a baby boy born without the ability to process dietary protein properly ...

Elevidys has been given full approval to treat ambulatory patients with DMD, with an accelerated approval in non-ambulatory ...

This new review article highlights the critical role of ribosome biogenesis in liver health and disease progression.

Discover a study that found that individuals with higher baseline IL-1β levels experienced greater improvements in liver ...

EMA accepts GSK’s MAA for linerixibat for cholestatic pruritus in patients with primary biliary cholangitis: London, UK Tuesday, June 24, 2025, 09:00 Hrs [IST] GSK plc announced ...